Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland
The Companies Have Already Partnered In Germany, France, And Poland
Executive Summary
Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.
You may also be interested in...
Neuraxpharm’s New Belgian Division Advances European Expansion Strategy
Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established.
Neuraxpharm Expands European Reach With Dutch Operation
Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.